ORIC PHARMACEUTICALS INC
ORICNASDAQTrading Snapshot
- Day Range
- $13.26 – $13.49
- 52-Week Range
- $7.23 – $14.93
- Volume
- $1.96B
- Avg Volume
- $1.72B
- Shares Outstanding
- 103.5M
- Next Earnings
- Nov 29, 2026
Fundamentals Snapshot
- Annual Revenue
- $129M
- Last Q Revenue
- $35M
- P/E Ratio
- -9.8
- P/S Ratio
- 0.0x
- EPS (TTM)
- $-1.30
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +24.3%
Why Investors Own ORIC
- ✓High-growth profile — revenue up -2.2% YoY with expanding US Equity exposure.
- ✓Healthy economics — 57% gross margin and 29% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
ORIC PHARMACEUTICALS INC
ORIC
StockOtter · stockotter.spaceAbout ORIC PHARMACEUTICALS INC
ORIC Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to discovering and advancing innovative treatments for cancer patients across the United States. The company's pipeline includes several key clinical-stage drug candidates. ORIC-533 is an oral small molecule designed to inhibit CD73, addressing resistance to both chemotherapy and immunotherapy. Another candidate, ORIC-944, is an allosteric inhibitor targeting the polycomb repressive complex 2, specifically for the treatment of prostate cancer. Furthermore, ORIC-114 is a brain-penetrant, orally administered, irreversible inhibitor crafted to precisely target epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2), demonstrating high potency against exon 20 insertion mutations. Beyond these advanced programs, ORIC Pharmaceuticals is also cultivating multiple early-stage precision medicines aimed at other mechanisms of cancer resistance. The company has established partnerships, including a licensing and collaboration agreement with Voronoi Inc., and a licensing agreement with Mirati Therapeutics, Inc. ORIC Pharmaceuticals was founded in 2014 and maintains its headquarters in South San Francisco, California.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
ORIC Pharmaceuticals, Inc. (ORIC) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
ORIC Pharmaceuticals, Inc. (ORIC) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Sept.
ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Sept. 02, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing and commercializing treatments that address
Dimensional Fund Advisors LP Boosts Holdings in Oric Pharmaceuticals, Inc. $ORIC
Dimensional Fund Advisors LP increased its holdings in shares of Oric Pharmaceuticals, Inc. (NASDAQ: ORIC) by 19.9% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commi
ORIC® Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Updates
Initiated Himalayas-1 global Phase 3 trial in patients with mCRPC previously treated with abiraterone Entered into a clinical trial collaboration and supply agreement with Bayer to provide darolutamide for Himalayas-1 An
ORIC Pharmaceuticals: Royalty-Free Phase 3 Economics Strengthen The Bull Case
ORIC Pharmaceuticals advances rinzimetostat into the global Phase 3 Himalayas-1 trial for mCRPC, with full global rights and royalty-free economics. ORIC's $419.7M cash position funds operations into 2H 2028, supporting